Tato čerstvá zpráva by mohla akcii $NVO nastartovat: Novo Nordisk (NVO) said Wednesday that oral semaglutide 25 mg (Wegovy in a pill) delivered 16.6% weight loss in people with obesity in a phase 3 trial compared with 2.7% for placebo in 64-week trial. 34.4% achieved at least 20% weight loss, versus 2.9% for placebo.
The safety and tolerability profile of oral semaglutide was also consistent with that for injectable Wegovy.
Oral semaglutide 25 mg also demonstrated improvements in the ability to perform everyday physical activities such as bending, standing, walking, being physically active, and improvements in cardiovascular risk factors.
The FDA is expected to complete NDA review by year-end. At present, no oral GLP-1 treatments for weight loss have been approved.
If approved by the FDA, the pill for weight management will be fully made in the U.S., with production already underway at Novo Nordisk’s significantly expanded manufacturing facility.
